Sancti Spiritus, Cuba, Aug 17 (Prensa Latina) The phase III clinical trial to evaluate the efficacy and safety of the neuroprotective drug NeuralCIM in patients with mild or moderate Alzheimer's amnestic variant is progressing positively today in this central province of Cuba.